Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
November 07 2017 - 9:00AM
Celsion Corporation (NASDAQ:CLSN) announced today that the Company
will host a conference call to discuss financial results for the
quarter ended September 30, 2017 and provide an update on its
development programs for ThermoDox®, its proprietary heat-activated
liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA
plasmid vector formulated into a nanoparticle with a non-viral
delivery system at 11:00 a.m. ET on Tuesday, November 14, 2017. To
participate in the call, interested parties may dial 1-877-830-2649
(Toll-Free/North America) or 1-785-424-1824 (International/Toll)
and ask for the Celsion Corporation 3rd Quarter 2017 Earnings Call
(Conference Code: 3840213) to register ten minutes before the call
is scheduled to begin. The call will also be broadcast live over
the internet at www.celsion.com.
The call will be archived for replay on Tuesday,
November 14, 2017 and will remain available until Tuesday, November
28, 2017. The replay can be accessed at 1-888-203-1112
(Toll-Free/North America) or 1-719-457-0820 (International/Toll)
using Conference Code: 3840213. An audio replay of the call
will also be available on the Company’s website, www.celsion.com,
for 90 days after 2:00 p.m. ET on Tuesday, November 14, 2017.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in development for other cancer indications.
The Company’s product pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies. For more information on Celsion,
visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor ContactJeffrey W. Church Sr.
Vice President and CFO 609-482-2455 jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Sep 2023 to Sep 2024